HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Cullinan Oncology (NASDAQ:CGEM) and maintains a $49 price target.
June 05, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cullinan Oncology (NASDAQ:CGEM) receives a reiterated Buy rating from HC Wainwright & Co. with a maintained $49 price target.
The reiterated Buy rating and maintained $49 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for Cullinan Oncology's stock. This news is likely to have a positive short-term impact on CGEM's stock price as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100